RALEIGH, N.C., Aug. 27 /PRNewswire/ -- LipoScience, Inc. announces a collaboration with BioReference Laboratories, Inc. to offer the NMR LipoProfile(R) test. Portions of the NMR LipoProfile test, developed by Raleigh-based medical technology company LipoScience, will be used by BioReference Laboratories in its new Advanced Cardiovascular Testing (ACT) program. The ACT program provides physicians a comprehensive cardiovascular report including a full suite of results to aid physicians in management of their patients’ cardiovascular health. The patient-friendly report also functions as a “Report Card” to help patients and their physicians track the results of the ACT test over time.
BioReference Laboratories, headquartered in Elmwood Park, NJ, is the largest independent regional clinical laboratory in the Northeast providing focused laboratory services on a national basis in the areas of oncology (primarily hematopathology), clinical genetics and correctional healthcare. The agreement with LipoScience will expand availability of the NMR LipoProfile test.
“This valuable collaboration with BioReference Laboratories builds on our corporate strategy to broaden access to the NMR LipoProfile test and decentralize clinical applications of NMR technology,” said Richard O. Brajer, president and CEO of LipoScience. The test uses NMR spectroscopy to analyze blood plasma samples and provide detailed information about the number of LDL particles in the bloodstream. The number of LDL particles is the optimal measure of LDL and of the heart disease risk that LDL causes.
Marc Grodman, MD, CEO of BRLI, stated: “We believe that ACT, our Advanced Cardiovascular Testing program, is a model for the way clinical laboratories can provide added value for both physicians and patients. We provide comprehensive information used by physicians in treating patients with cardiovascular risk in a format that patients can easily understand. The NMR LipoProfile test, developed by LipoScience, is a critical element in this outstanding report and we are extremely pleased to be working with LipoScience in this program.”
LDL particles are containers in the blood that carry the so-called “bad” cholesterol. The number of these particles (LDL-P) is a better indicator of heart disease risk than the amount of cholesterol the particles contain. The NMR LipoProfile test measures LDL-P and provides related information, enabling doctors to optimally manage the heart disease risk of their patients.
LipoScience markets the NMR LipoProfile test to clinicians, commercial diagnostic laboratories and clinical research clients. Founded in 1994, LipoScience introduced the NMR LipoProfile blood test for clinical research in 1997 and for use in patient care in 1999.
About BioReference Laboratories, Inc.
BRLI is a full service clinical laboratory with specialty capability in areas such as genomics, oncology, correctional health and complimentary medicine. PSIMedica, a business unit of the company, is a clinical knowledge management (CKM) organization offering an array of information solutions for reducing healthcare costs and improving quality performance. BRLI provides a comprehensive connectivity solution to physicians as well as other laboratories, which includes laboratory reporting and ordering, as well as laboratory to physician communications and cumulative reporting, through CareEvolve, its web-based healthcare portal.
LipoScience, Inc.
CONTACT: Susan Taylor of LipoScience, Inc., +1-919-256-1048
Web site: http://www.liposcience.com/
